Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years

Clinical Therapeutics

Volumn 34, Issue 10, 2012, Pages 2082-2090

  Norwood, Paul ^a   Liutkus, Joanne F ^b   Haber, Harry ^c   Pintilei, Ella ^d   Boardman, Marilyn K ^e   Trautmann, Michael E ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cambridge Memorial Hospital   (Canada)

^c Department of Statistics   (United States)

^d Nutrition and Metabolic Diseases   (Romania)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide; GLP 1 receptor agonist; Glucose control; HbA1c; Metformin; Type 2 diabetes mellitus; TZD

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC PATIENT; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FEMALE; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE NODULE; INTENTION TO TREAT ANALYSIS; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHINOPHARYNGITIS; SINUSITIS; STUDENT T TEST; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; RECEPTORS, GLUCAGON; THIAZOLIDINEDIONES; VENOMS;

EID: 84867344249     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.007     Document Type: Article

References (31)

1. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
2. Bergenstal R.M., Wysham C., MacConell L., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439. DURATION-2 Study Group.
3. Blevins T., Pullman J., Malloy J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:1301-1310. DURATION-5 Study Group.
4. Diamant M., Van Gaal L., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243. DURATION-3 Study Group.
5. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. DURATION-1 Study Group.
6. Russell-Jones D., Cuddihy R.M., Hanefeld M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012, 35:252-258. DURATION-4 Study Group.
7. MacConell L., Brown C., Gurney K., Han J. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012, 5:29-41.
8. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
9. Samuel V.T., Petersen K.F., Shulman G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375:2267-2277.
10. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011, 11:115-128.
11. Berlie H.D., Kalus J.S., Jaber L.A. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007, 76:279-289.
12. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
13. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
14. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
15. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
16. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
17. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
18. Zinman B., Hoogwerf B.J., Durán García S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
19. Liutkus J., Rosas Guzman J., Norwood P., et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 2010, 12:1058-1065.
20. Pencek R., Brunell S.C., Li Y., et al. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract 2012, 18:227-237.
21. Norwood P., Pintilei E., Pop L., et al. Safety of exenatide once weekly in patients with type 2 diabetes treated with a thiazolidinedione. Diabetes 2010, 59. Abstract 715-P.
22. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997, 277:925-926.
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. CPMP/ICH/375/95 Accessed April 3, 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf.
24. Diamant M., Van Gaal L., Stranks S., et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012, 35:683-689.
25. DeYoung M.B., MacConell L., Sarin V., et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011, 13:1145-1154.
26. Kung J., Henry R.R. Thiazolidinedione safety. Expert Opin Drug Saf 2012, 11:565-579.
27. Jain R., Mullins C.D., Lee H., Wong W. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. Res Social Adm Pharm 2012, 8:47-59.
28. Hurren K.M., Taylor T.N., Jaber L.A. Antidiabetic prescribing trends and predictors of thiazolidine discontinuation following the 2007 rosigitazone safety alert. Diabetes Res Clin Pract 2011, 93:49-55.
29. Vilsbøll T., Christensen M., Junker A.E., et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
30. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
31. Buse J.B., Drucker D.J., Taylor K.L., et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33:1255-1261.